• Zymeworks Inc. has released its fourth quarter and full-year 2025 results, reporting a net loss of US$41.21 million for the quarter and US$81.13 million for the year, alongside basic and diluted loss per share from continuing operations of US$0.55 for the quarter and US$1.08 for the year.
• On the same day, the company also filed a US$79.29 million shelf registration for 3,404,536 common shares under an ESOP-related offering, highlighting both ongoing capital needs and an increased emphasis on equity-based compensation and potential dilution.
• We’ll now examine how the wider quarterly loss alongside the new ESOP-related shelf registration could influence Zymeworks’ longer-term investment narrative.

Find 49 companies with promising cash flow potential yet trading below their fair value.

Zymeworks Investment Narrative Recap

To own Zymeworks, you need to believe its partnered oncology assets and early-stage pipeline can eventually turn irregular milestones and royalties into a more durable earnings base. The wider Q4 loss and ongoing annual net loss underline how dependent that path is on external partners and capital access. The new ESOP-related shelf registration modestly increases near term dilution risk, but does not appear to materially change the key near term catalyst or the principal execution risks around partnered programs.

The most relevant recent development here is the US$79.29 million shelf registration for 3,404,536 common shares tied to the ESOP. Coming shortly after a year in which Zymeworks still posted an US$81.13 million net loss, it reinforces that equity remains a meaningful part of the company’s funding toolkit. For investors focused on pipeline and partnership milestones as catalysts, it also highlights that future upside is likely to come alongside ongoing dilution and evolving capital allocation choices.

Yet against that potential, the risk that irregular partner milestones and royalties fail to keep pace with Zymeworks’ cash needs is something investors should be aware of...

Zymeworks' narrative projects $150.9 million revenue and $24.2 million earnings by 2028.

Uncover how Zymeworks' forecasts yield a $36.46 fair value, a 51% upside to its current price.

Exploring Other Perspectives

Before this earnings miss, the most optimistic analysts were assuming revenue could reach about US$228.1 million by 2028 and earnings around US$32.3 million, which is a far more upbeat story than the current deep losses and fresh ESOP dilution imply, so it is worth recognizing how wide that gap is when you weigh today’s numbers against those pre news expectations.

Explore 3 other fair value estimates on Zymeworks - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Zymeworks research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Zymeworks research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zymeworks' overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 16 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.